Aripiprazole

Aripiprazole is an atypical, or second-generation, antipsychotic developed by Otsuka Pharmaceutical and first approved in 2002. Chemically it belongs to the phenylpiperazine class. It stands out among antipsychotics for its distinctive receptor pharmacology: rather than fully blocking dopamine receptors, it partially activates them, a property that led to its being called a dopamine system stabilizer ^[2].

The drug is used to treat schizophrenia and the manic and mixed episodes of bipolar disorder, and as an add-on to antidepressants in major depressive disorder that responds only partially to those drugs. It is also approved for irritability associated with autism in children and for tic disorders such as Tourette syndrome. Its efficacy in schizophrenia was established in randomized, placebo-controlled trials; a pivotal four-week study found aripiprazole improved both positive and negative symptoms compared with placebo, with fewer movement side effects and less prolactin elevation than the older drug haloperidol ^[1]. Pooled analyses supported its usefulness in related conditions such as schizoaffective disorder ^[3].

Aripiprazole's balanced action tends to produce less of the heavy sedation, movement disorders, and prolactin elevation associated with older antipsychotics, though it is not free of side effects ^[1]. It is generally regarded as having a comparatively modest effect on body weight relative to some other atypical agents.

Common side effects include restlessness or an inner urge to move (akathisia), insomnia, headache, and nausea. A notable and less obvious risk, highlighted by drug regulators, is the emergence of impulse-control problems such as compulsive gambling, shopping, or eating in a minority of users, thought to relate to the drug's dopamine-activating action. Serious but rare reactions include neuroleptic malignant syndrome and tardive dyskinesia.

Aripiprazole is a prescription medicine available as ordinary and orally disintegrating tablets, an oral solution, short-acting injections, and long-acting injectable forms given every few weeks to support consistent treatment. A version with an embedded ingestible sensor was also developed to track whether doses were taken.

Aripiprazole is a prescription medicine. The most characteristic side effect is akathisia, an inner restlessness, along with insomnia or drowsiness, anxiety, nausea, and headache; weight gain and metabolic changes occur but tend to be milder than with some other antipsychotics, though glucose and lipids are still monitored. A notable and sometimes overlooked risk is impulse-control problems such as compulsive gambling, shopping, or hypersexuality, which usually ease when the dose is lowered or stopped. Rare serious effects include neuroleptic malignant syndrome and tardive dyskinesia. It carries boxed warnings for increased death in elderly patients with dementia-related psychosis and for suicidal thinking in young people, and its dose is adjusted when combined with drugs that block the CYP2D6 or CYP3A4 enzymes.

Aripiprazole is metabolized by CYP2D6 and CYP3A4. When combined with CYP3A4 inhibitors like ketoconazole, itraconazole, or clarithromycin, the dose should be reduced to approximately one-quarter of the normal dose ^[31]. In patients who are CYP2D6 poor metabolizers, dose reduction is also recommended ^[32]. These are pharmacokinetic interactions; the inhibitors reduce aripiprazole's metabolism, causing its blood levels to increase substantially. What remains unexplored is the effect of CYP2D6 inducers, and interactions with drugs that depend on aripiprazole's inhibition of their own metabolism are underdocumented.

Checking a whole stack? Run it through interactions + stacks.

Aripiprazole was discovered by the Japanese company Otsuka Pharmaceutical, whose chemists set out to design an antipsychotic that would stabilize rather than simply block dopamine transmission. The result was a novel dopamine D2 partial agonist, a mechanism distinct from the full receptor blockade of earlier drugs. The United States Food and Drug Administration approved aripiprazole, sold as Abilify, in November 2002 for schizophrenia, and its indications later expanded to bipolar disorder, adjunctive treatment of major depression, and irritability in autism. To improve adherence, long-acting injectable formulations such as Aristada were subsequently developed, allowing dosing on a monthly or longer schedule.

Aripiprazole is often chosen for its relatively favorable metabolic and sedation profile compared with several other atypical antipsychotics, making it attractive for long-term treatment. Its partial-agonist mechanism, sometimes described as dopamine system stabilization, tends to produce less prolactin elevation and fewer movement side effects, which many patients and prescribers value. It is used across schizophrenia, bipolar disorder, and as an add-on in depression, and the availability of long-acting injections supports adherence for those who struggle with daily pills. Balanced against these strengths is the recognized, if uncommon, risk of impulse-control problems such as compulsive gambling, an effect linked to the same dopamine-activating pharmacology.